Biomea Fusion (BMEA) Free Cash Flow (2020 - 2026)
Biomea Fusion (BMEA) posted Free Cash Flow of -$11.7 million for Q1 2026, up 12.41% sequentially from -$13.3 million in Q4 2025, and up 54.54% YoY from -$7.6 million in Q1 2025.
Biomea Fusion (BMEA) Free Cash Flow (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Free Cash Flow for 7 years, with the latest figure at -$11.7 million in Q1 2026.
- Quarterly Free Cash Flow rose 54.54% year-over-year to -$11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.8 million (up 48.67% YoY) and the FY2025 annual result came in at -$69.8 million, up 39.35% from the prior year.
- Free Cash Flow advanced to -$11.7 million in Q1 2026 per BMEA's latest filing, from -$13.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$10.1 million in Q1 2022 and troughed at -$32.7 million in Q2 2024.
- A 5-year average of -$21.1 million and a median of -$21.8 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2026: Free Cash Flow slumped 167.12% in 2023, then jumped 54.54% in 2026.
- Over 5 years, Free Cash Flow stood at -$20.9 million in 2022, then decreased by 4.4% to -$21.8 million in 2023, then slipped by 13.77% to -$24.8 million in 2024, then soared by 46.36% to -$13.3 million in 2025, then grew by 12.41% to -$11.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$11.7 million, -$13.3 million, and -$11.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -10.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.03 Mn |
| Jun 30, 2026 | -10.03 Mn |
| Mar 31, 2026 | -11.67 Mn |
| Mar 31, 2026 | -11.67 Mn |
| Dec 31, 2025 | -13.32 Mn |
| Dec 31, 2025 | -13.32 Mn |
| Sep 30, 2025 | -11.55 Mn |
| Sep 30, 2025 | -11.55 Mn |
| Jun 30, 2025 | -19.21 Mn |
| Jun 30, 2025 | -19.21 Mn |
| Mar 31, 2025 | -25.67 Mn |
| Mar 31, 2025 | -25.67 Mn |
| Dec 31, 2024 | -24.84 Mn |
| Dec 31, 2024 | -24.84 Mn |
| Sep 30, 2024 | -25.40 Mn |
| Sep 30, 2024 | -25.40 Mn |
| Jun 30, 2024 | -32.70 Mn |
| Jun 30, 2024 | -32.70 Mn |
| Mar 31, 2024 | -32.07 Mn |
| Mar 31, 2024 | -32.07 Mn |